Analytical chemistry at the Games of the XXIIIrd Olympiad in Los Angeles, 1984.

Catlin, Don H.; Kammerer, R. Craig; Hatton, Caroline K.; Sekera, Michael H.; Merdink, James L.

doi:10.1093/clinchem/33.2.319

Cited by 107 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For both studies, individuals qualifying on telephone screen are then evaluated at a screening interview, where they receive: (1) demographic questions; (2) the Structured Clinical Interview for DSM‐IV (SCID) to assess life‐time psychiatric and substance‐use diagnoses; (3) detailed questions about life‐time use of AAS and other performance‐enhancing drugs, if any, including questions about specific drugs used, dosages and life‐time duration of exposure; (4) the self‐reported International Index of Erectile Function (IIEF) ; (5) measurements of height, weight and body fat; and (6) collection of hair and urine samples. Urine samples are tested for AAS using methods described previously . Urine samples are also tested for opiates, amphetamines, cannabis, cocaine and phencyclidine, and for the performance‐enhancing drug clenbuterol.…”

Section: Methodsmentioning

confidence: 99%

Prolonged hypogonadism in males following withdrawal from anabolic–androgenic steroids: an under‐recognized problem

et al. 2015

View full text Add to dashboard Cite

Aims To assess the frequency and severity of hypogonadal symptoms in male long-term anabolic-androgenic steroid (AAS) misusers who have discontinued AAS use. Design Cross-sectional, naturalistic. Setting Outpatient facility. Participants Twenty-four male former long-term AAS users and 36 non-AAS-using weightlifters, recruited by advertisement in Massachusetts, USA. Five of the former users were currently receiving treatment with physiologic testosterone replacement, leaving 19 untreated users for the numerical comparisons below. Measurements The Structured Clinical Interview for DSM-IV, questions regarding history of AAS use, physical examination, serum hormone determinations, and the International Index of Erectile Function (IIEF). Findings Compared with the 36 non-AAS-using weightlifters, the 19 untreated former AAS users displayed significantly smaller testicular volumes (estimated difference [95% confidence interval (CI)]: 2.3 [0.1, 4.5] ml; p = 0.042) and lower serum testosterone levels (estimated difference: 131 [25, 227] dL; p = 0.009), with five users showing testosterone levels below 200 ng/dL despite abstinence from AAS for 3–26 months. Untreated former users also displayed significantly lower scores on the IIEF Sexual Desire subscale (estimated difference: 2.4 [1.3, 3.5] points on a 10-point scale; p < 0.001). In the overall group of 24 treated plus untreated former users, 7 (29%) had experienced major depressive episodes during AAS withdrawal; 4 of these had not experienced major depressive episodes at any other time. Two men (8%) had failed to regain normal libidinal or erectile function despite adequate replacement testosterone treatment. Conclusions Among long-term anabolic-androgenic steroid misusers, anabolic-androgenic steroid-withdrawal hypogonadism appears to be common, frequently prolonged, and associated with substantial morbidity.

show abstract

Section: Methodsmentioning

confidence: 99%

Prolonged hypogonadism in males following withdrawal from anabolic–androgenic steroids: an under‐recognized problem

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The steroid screen which gave the T/E estimates included sample preparation by addition of [16,16,17‐ 2 H] testosterone, enzymatic deconjugation with β‐glucuronidase, automated SPE (Rapid Trace Zymark, Hopkinton, MA, USA) on C 18 disks, formation of trimethylsilyl derivatives and GC/MS analysis as described before 12. This screen includes positive and negative quality control samples whose estimated T/Es must fall within tolerance ranges and are monitored on QC charts.…”

Section: Methodsmentioning

confidence: 99%

A rapid screening assay for measuring urinary androsterone and etiocholanolone ?13C (?) values by gas chromatography/combustion/isotope ratio mass spectrometry

Aguilera

Chapman

Catlin

2000

Rapid Commun. Mass Spectrom.

View full text Add to dashboard Cite

A gas chromatography/combustion/isotope ratio mass spectrometry (GC/C/IRMS) method is described and validated for measurement of δ13C values of the acetate derivatives of urinary etiocholanolone and androsterone. The analysis was performed with only 2 mL of urine. The sample preparation consisted of deconjugation with β‐glucuronidase, solid phase extraction, and derivatization with acetic anhydride and pyridine. The within‐assay precision of two quality control (QC) urine samples ranged from 0.5 to 2.1 CV%. The between‐assay precision in the same QC urines ranged from 1.7 to 3.4 CV%. Administration of testosterone enanthate to a subject resulted in a 6‰ decrease in δ13C values from −25‰ (baseline) to −31‰. Two weeks after testosterone administration was discontinued, the δ13C values remained abnormally low while the urine testosterone/epitestosterone (T/E) ratio returned to less than 6. This relatively simple method is useful for rapidly screening a large number of urine samples, including those with T/E <6. Copyright © 2000 John Wiley & Sons, Ltd.

show abstract

“…19-Nortestosterone and its metabolites were extracted and submitted to gas chromatographyimass spectrometry. To determine the glucuronides of 19-nortestosterone, we dried and hydrolyzed samples (19,20). Analyses were performed with a Hewlett-Packard model 5988A gas chromatograph/mass spectrometer fitted with a Hewlett-Packard HP1 methylsilicon column (16.6 mm x 0.2 mm; 0.33-km film thickness).…”

Section: Methodsmentioning

confidence: 99%

Development of a bioartificial liver: Properties and function of a hollow-fiber module inoculated with liver cells

Rózga

1993

Hepatology

View full text Add to dashboard Cite

We have developed a bioartificial liver support system utilizing hollow-fiber bioreactor, plasmapheresis and microcarrier cell culture technologies. Liver cells were obtained through portal vein perfusion with ethylenediaminetetraacetate or ethylenediaminetetraacetate/collagenase. A mathematical model of mass transport in a hollow-fiber module, at various plasma flow velocities and system configurations, was developed. The bioartificial liver's ability to carry out specific differentiated metabolic liver functions was tested in vitro and in vivo. A reproducible large-animal model of acute ischemic liver failure was developed. Most major first-generation cyclosporine and 19-norterstosterone metabolites were isolated after substrate addition to the bioartificial liver in vitro. After bioartificial liver treatment for 6 hr (with dog or pig liver cells), dogs with acute liver failure had significantly lower serum ammonia and lactate levels and significantly higher serum glucose levels than did control animals treated with a bioartificial liver system inoculated with microcarriers alone. In addition, bioartificial liver-treated animals had significantly higher mean systolic blood pressures than did controls. Liver cell viability at the end of the 6-hr in vivo experiment was greater than 90%.

show abstract

Analytical chemistry at the Games of the XXIIIrd Olympiad in Los Angeles, 1984.

Cited by 107 publications

References 0 publications

Prolonged hypogonadism in males following withdrawal from anabolic–androgenic steroids: an under‐recognized problem

Prolonged hypogonadism in males following withdrawal from anabolic–androgenic steroids: an under‐recognized problem

A rapid screening assay for measuring urinary androsterone and etiocholanolone ?13C (?) values by gas chromatography/combustion/isotope ratio mass spectrometry

Development of a bioartificial liver: Properties and function of a hollow-fiber module inoculated with liver cells

Contact Info

Product

Resources

About